Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
Guardado en:
Autores principales: | Andrew Haydon, Jessica C Hassel, Jeffrey A Sosman, Sunandana Chandra, Ryan Sullivan, Mario E Lacouture, Meghan J Mooradian, Alexander Menzies, Douglas B Johnson, Fei Ye, Prachi Bhave, Steven T Chen, Georgina Long, Briana Rose Halle, Farzana Y Zaman, Anna K Dewan, Rebecca Irlmeier, Paras Mehta, Nicholas R Kurtansky, Jacob S Choi, Tracey S Otto, Florentia Dimitriou, Veronica M Rotemberg |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2404ddf91eb64426ad24a0c1ae12dd85 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Psoriasis and Cardiometabolic Diseases: The Impact of Inflammation on Vascular Health
por: Teklu M, et al.
Publicado: (2021) -
The effect of biosimilar administration on clinical outcomes in patients with adalimumab‐controlled psoriasis
por: M. Panahi, et al.
Publicado: (2021) -
Psoriasis
por: MOLL LEE,NORMAN
Publicado: (1947) -
Psoriasis and alcohol
por: Svanström C, et al.
Publicado: (2019) -
Psoriasis in children
por: Pinson R, et al.
Publicado: (2016)